[1]崔雯锦,陈国芳,刘超.免疫检查点抑制剂相关内分泌疾病诊治研究进展[J].国际内分泌代谢杂志,2021,41(02):116-123.[doi:10.3760/cma.j.cn121383-20200331-03086]
　Cui Wenjin,Chen Guofang,Liu Chao..Progress in the diagnosis and treatment of immune checkpoint inhibitors related endocrine diseases[J].International Journal of Endocrinology and Metabolism,2021,41(02):116-123.[doi:10.3760/cma.j.cn121383-20200331-03086]
点击复制

免疫检查点抑制剂相关内分泌疾病诊治研究进展()
分享到：

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
41
期数:
2021年02期
页码:
116-123
栏目:
综述
出版日期:
2021-03-20

文章信息/Info

Title:
Progress in the diagnosis and treatment of immune checkpoint inhibitors related endocrine diseases
作者:
崔雯锦; 陈国芳; 刘超
南京中医药大学附属中西医结合医院,江苏省中医药研究院内分泌科 210028
Author(s):
Cui Wenjin;  Chen Guofang;  Liu Chao.
Department of Endocrinology, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing 210028, China
关键词:
免疫检查点抑制剂;  免疫相关不良事件;  内分泌腺体;  腺体功能紊乱
Keywords:
Immune checkpoint inhibitors;  Immune-related adverse events;  Endocrine glands;  Endocrine dysfunction
DOI:
10.3760/cma.j.cn121383-20200331-03086
摘要:
免疫检查点抑制剂(immune checkpoint inhibitors,ICIs)作为新型抗肿瘤药物,能显著提高晚期癌症的生存率。随着ICIs的广泛应用,其所诱发的免疫相关不良事件(immune-related adverse events,irAEs)也越发多见,涉及多个器官,常见受累内分泌腺体包括甲状腺和垂体,其次为肾上腺、胰腺和甲状旁腺。irAEs影响各腺体功能。尽管内分泌系统不是常见的受累器官,但因症状不典型或比较轻微,易被误诊、忽视,可能会影响患者的生活质量、肿瘤治疗进展,甚至发生内分泌危象。目前,国外已发表相关指南,国内亟需肿瘤科与内分泌科医师共同完善ICIs诱导的内分泌相关疾病诊治指南,指导临床改善晚期肿瘤患者的药物不良反应。
Abstract:
As new antitumor drugs, immune checkpoint inhibitors(ICIs)can significantly improve the survival rate of some advanced cancers. With the wide application of ICIs, immune-related adverse events(irAEs)induced by ICIs are more common, including a wide range of organs. Common affected endocrine glands including the thyroid gland and pituitary gland, while adrenal glands, pancreas and parathyroid glands are relatively rare. IrAEs affect the function of each gland. Although endocrine system is not a common target, it is easyly to be misdiagnosed and neglected because of atypical or mild symptoms, which may affect patients' quality of life, tumor treatment progress, and even induce endocrine crisis if without treatment in time. It is necessary for domestic oncologist and endocrinologists to work together to improve the guidelines of endocrine-related diseases induced by ICIs, which help reduce adverse drug reactions.

参考文献/References:

[1] Arima H,Iwama S,Inaba H,et al. Management of immune-related adverse events in endocrine organs induced by immune checkpoint inhibitors:clinical guidelines of the Japan Endocrine Society[J].Endocr J,2019,66(7):581-586.DOI:10.1507/endocrj.EJ19-0163.
[2] Brahmer JR,Lacchetti C,Schneider BJ,et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy:American Society of Clinical Oncology Clinical Practice Guideline[J].J Clin Oncol,2018,36(17):1714-1768.DOI:10.1200/JCO.2017.77.6385.
[3] 李佳蓉,关海霞. 内分泌学与肿瘤学医师须知:免疫检查点抑制剂致内分泌腺体损伤[J].中华内分泌代谢杂志,2019,35(7):548-553.DOI:10.3760/cma.j.issn.1000-6699.2019.07.002.
[4] Michot JM,Bigenwald C,Champiat S,et al. Immune-related adverse events with immune checkpoint blockade:a comprehensive review[J].Eur J Cancer,2016,54:139-148.DOI:10.1016/j.ejca.2015.11.016.
[5] Mellman I,Coukos G,Dranoff G. Cancer immunotherapy comes of age[J].Nature,2011,480(7378):480-489.DOI:10.1038/nature10673.
[6] Chang LS,Barroso-Sousa R,Tolaney SM,et al. Endocrine toxicity of cancer immunotherapy targeting immune checkpoints[J].Endocr Rev,2019,40(1):17-65.DOI:10.1210/er.2018-00006.
[7] Byun DJ,Wolchok JD,Rosenberg LM,et al. Cancer immunotherapy-immune checkpoint blockade and associated endocrinopathies[J].Nat Rev Endocrinol,2017,13(4):195-207.DOI:10.1038/nrendo.2016.205.
[8] Barroso-Sousa R,Barry WT,Garrido-Castro AC,et al. Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens:a systematic review and meta-analysis[J].JAMA Oncol,2018,4(2):173-182.DOI:10.1001/jamaoncol.2017.3064.
[9] Lee H,Hodi FS,Giobbie-Hurder A,et al. Characterization of thyroid disorders in patients receiving immune checkpoint inhibition therapy[J].Cancer Immunol Res,2017,5(12):1133-1140.DOI:10.1158/2326-6066.CIR-17-0208.
[10] Osorio JC,Ni A,Chaft JE,et al. Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer[J].Ann Oncol,2017,28(3):583-589.DOI:10.1093/annonc/mdw640.
[11] Torimoto K,Okada Y,Nakayamada S,et al. Anti-PD-1 antibody therapy induces Hashimoto's disease with an increase in peripheral blood follicular helper T cells[J].Thyroid,2017,27(10):1335-1336.DOI:10.1089/thy.2017.0062.
[12] 方晨,郭鹤鸣,黄韵,等. 警惕肿瘤免疫治疗的内分泌系统不良反应[J].国际内分泌代谢杂志,2019,39(5):327-331,336.DOI:10.3760/cma.j.issn.1673-4157.2019.05.010.
[13] Maekura T,Naito M,Tahara M,et al. Predictive factors of nivolumab-induced hypothyroidism in patients with non-small cell lung cancer[J].In Vivo,2017,31(5):1035-1039.DOI:10.21873/invivo.11166.
[14] Dudzińska M,Szczyrek M,Wojas-Krawczyk K,et al. Endocrine adverse events of nivolumab in non-small cell lung cancer patients-literature review[J].Cancers(Basel),2020,12(8):2314.DOI:10.3390/cancers12082314.
[15] Iwama S,De Remigis A,Callahan MK,et al. Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody[J].Sci Transl Med,2014,6(230):230r-245r.DOI:10.1126/scitranslmed.3008002.
[16] Del RJ,Cordes LM,Klubo-Gwiezdzinska J,et al. Endocrine-related adverse events related to immune checkpoint inhibitors:proposed algorithms for management[J].Oncologist,2020,25(4):290-300.DOI:10.1634/theoncologist.2018-0470.
[17] Faje AT,Sullivan R,Lawrence D,et al. Ipilimumab-induced hypophysitis:a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma[J].J Clin Endocrinol Metab,2014,99(11):4078-4085.DOI:10.1210/jc.2014-2306.
[18] Hughes J,Vudattu N,Sznol M,et al. Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy[J].Diabetes Care,2015,38(4):e55-e57.DOI:10.2337/dc14-2349.
[19] Godwin JL,Jaggi S,Sirisena I,et al. Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer[J].J Immunother Cancer,2017,5:40.DOI:10.1186/s40425-017-0245-2.
[20] Haissaguerre M,Hescot S,Bertherat J,et al. Expert opinions on adrenal complications in immunotherapy[J].Ann Endocrinol(Paris),2018,79(5):539-544.DOI:10.1016/j.ando.2018.07.002.
[21] Paepegaey AC,Lheure C,Ratour C,et al. Polyendocrinopathy resulting from pembrolizumab in a patient with a malignant melanoma[J].J Endocr Soc,2017,1(6):646-649.DOI:10.1210/js.2017-00170.
[22] Bornstein SR,Allolio B,Arlt W,et al. Diagnosis and treatment of primary adrenal insufficiency:an Endocrine Society Clinical Practice Guideline[J]. J Clin Endocrinol Metab,2016,101(2):364-389.DOI:10.1210/jc.2015-1710.
[23] Win MA,Thein KZ,Qdaisat A,et al. Acute symptomatic hypocalcemia from immune checkpoint therapy-induced hypoparathyroidism[J].Am J Emerg Med,2017,35(7):1035-1039.DOI:10.1016/j.ajem.2017.02.048.
[24] Piranavan P,Li Y,Brown E,et al. Immune checkpoint inhibitor-induced hypoparathyroidism associated with calcium-sensing receptor-activating autoantibodies[J].J Clin Endocrinol Metab,2019,104(2):550-556.DOI:10.1210/jc.2018-01151.
[25] Faje A. Immunotherapy and hypophysitis:clinical presentation,treatment,and biologic insights[J].Pituitary,2016,19(1):82-92.DOI:10.1007/s11102-015-0671-4.
[26] Teraoka S,Fujimoto D,Morimoto T,et al. Early immune-related adverse events and association with outcome in advanced non-small cell lung cancer patients treated with nivolumab:a prospective cohort study[J].J Thorac Oncol,2017,12(12):1798-1805.DOI:10.1016/j.jtho.2017.08.022.

相似文献/References:

[1]方晨 郭鹤鸣 黄韵 陈小红 李思诚 刘翠平 胡吉.警惕肿瘤免疫治疗的内分泌系统不良反应[J].国际内分泌代谢杂志,2019,39(05):327.[doi:10.3760/cma.j.issn.1673-4157.2019.05.010]
　Fang Chen,Guo Heming,Huang Yun,et al.Be aware of endocrinological side effects of cancer immunotherapy[J].International Journal of Endocrinology and Metabolism,2019,39(02):327.[doi:10.3760/cma.j.issn.1673-4157.2019.05.010]
[2]崔雯锦,胡欣,韦晓,等.免疫检查点抑制剂诱发甲状腺功能紊乱的研究进展[J].国际内分泌代谢杂志,2021,41(01):33.[doi:10.3760/cma.j.cn121383-20200909-09019]
　Cui Wenjin,Hu Xin,Wei Xiao,et al.Progress in immune checkpoint inhibitors induced thyroid dysfunction[J].International Journal of Endocrinology and Metabolism,2021,41(02):33.[doi:10.3760/cma.j.cn121383-20200909-09019]

备注/Memo

备注/Memo:
通信作者:陈国芳,Email:chenguofang9801@126.com 基金项目:国家自然科学基金(81800756); 江苏省第十六批“六大人才高峰”项目(WSN-035)
更新日期/Last Update: 2021-03-20